- Details
- Alicia Morgans and Daniel Sentana Lledo discuss a groundbreaking analysis on data from the CHAARTED study that examined how quality of life impacts survival in metastatic hormone-sensitive prostate cancer patients. Interestingly, patients with better quality of life scores at three months exhibited longer survival times. However, the role of docetaxel (a chemotherapeutic) treatment in this finding...
|
- Details
- Alicia Morgans hosts Tian Zhang to present an update from her presentation on the STARTAR trial, focusing on treatment intensification for high-risk prostate cancer with biochemical recurrence. STARTAR builds on an earlier trial, STREAM, by combining hormone deprivation with apalutamide, salvage radiation, and six cycles of docetaxel. The study focused on patients with Gleason 7 with nodal positiv...
|
- Details
- Andrea Miyahira and Susan Halabi discuss Dr Halabi's prognostic model for overall survival in patients with metastatic castration-resistant prostate cancer. Originating in the early 2000s, the model sought to provide patients with more specific information about their prognoses and categorize them into different risk groups. Dr. Halabi's model comprises eight easily obtainable clinical variables,...
|
- Details
- In a conversation between Alicia Morgans and Atish Choudhury, they discuss a study called A-DREAM that is examining the right balance of treatment duration for patients with metastatic prostate cancer. They note that androgen deprivation therapy (ADT) works well for many patients, but it can also lead to complications such as weight gain, muscle loss, and cardiovascular issues over time. To combat...
|
- Details
- In a conversation with Alicia Morgans, Stephen Freedland discusses a study he presented that analyzes Veterans Affairs’ data on men who had received either surgery or radiation therapy for prostate cancer and later developed a biochemical recurrence. The focus is on the 'doubling time' of PSA, a significant prognostic factor. According to the study, the majority of patients with a doubling time of...
|
- Details
- In a conversation between Alicia Morgans and David Olmos, they discussed the exciting findings from Olmos' presentation focusing on prostate cancer patients with BRCA mutations. Dr. Olmos highlighted that BRCA1 and BRCA2 mutation patients, regardless of germline or somatic origin, generally have worse outcomes compared to other patients. The CAPTURE study he spearheaded, which involved multiple co...
|
- Details
- Ursula Vogl converses with Alicia Morgans about determining optimal therapeutic strategies in treating metastatic hormone-sensitive prostate cancer. Vogl discusses the selection between doublet and triplet therapies, acknowledging that there are no absolute answers. She presents her pro-triplet therapy argument from the European Association of Urology (EAU) 2023 meeting. Referencing key trials suc...
|
- Details
- Jeremie Calais discusses a retrospective analysis of the use of PSMA PET in salvage radiotherapy with Alicia Morgans. The study focused on the application of PSMA PET findings to the treatment of patients with biochemical recurrence after radical prostatectomy, with approximately 4-5 years of follow-up. They discovered that disease presence correlates with negative outcomes and that the number of...
|
- Details
- Phillip Koo interviews Ken Herrmann about his presentation focusing on a predictive model for 177Lu-PSMA-617. Herrmann explains the difference between a prognostic tool, which indicates a patient's overall prognosis, and a predictive tool that specifies whether a patient is likely to benefit from a particular therapy. He presents a model based on data from the Vision trial and explains how this mo...
|
- Details
- Tanya Dorff shares her team’s insights on research into CAR T therapy targeting Prostate Stem Cell Antigen (PSCA). Their analysis shows promise in managing advanced castration-resistant prostate cancer. However, this treatment also presents challenges, including the issue of dose escalation due to the occurrence of high-grade cystitis, a complication encountered during the trials. In response, Dor...
|
